Neuroglobin Can Prevent or Reverse Glaucomatous Progression in DBA/2J Mice.

Area of Science:

• Ophthalmology
• Neuroscience
• Mitochondrial Biology

Background:

• Hereditary optic neuropathies are linked to mitochondrial dysfunction.
• Glaucoma models, like DBA/2J mice, show elevated intraocular pressure and retinal ganglion cell degeneration.
• Mitochondrial dysfunction, including compromised respiratory chain activity, precedes neuronal loss in these mice.

Purpose of the Study:

• To investigate if preserving mitochondrial bioenergetics can prevent optic neuropathy in a glaucoma mouse model.
• To determine the neuroprotective potential of neuroglobin in glaucoma.
• To evaluate gene therapy using adeno-associated viral vectors to restore neuroglobin levels in the retina.

Main Methods:

• DBA/2J mice were used as a model for glaucoma.
• Mitochondrial respiratory chain activity and protein levels were assessed in optic nerves and retinas.
• Gene therapy with adeno-associated viral vectors was administered to restore neuroglobin levels at different ages.
• Neuronal survival, respiratory chain activity, and visual cortex activity were evaluated post-treatment.

Main Results:

• Glaucoma in DBA/2J mice is associated with mitochondrial dysfunction and reduced mitochondrial protein levels, including neuroglobin.
• Early gene therapy (2-month-old mice) impeded glaucoma development, preserving neurons and mitochondrial/visual cortex activity.
• Late gene therapy (8-month-old mice) preserved surviving neurons' function and maintained respiratory chain activity.

Conclusions:

• Restoring neuroglobin levels via gene therapy can prevent or mitigate glaucoma development and progression.
• Neuroglobin demonstrates significant neuroprotective effects in the context of mitochondrial dysfunction and optic neuropathy.
• This approach holds promise as a potential therapeutic strategy for glaucoma treatment.